Alpha Cancer Technologies is Drug Discovery in Canada that focus on proprietary drugs business. Founded in 2008. They cover business area such as developer, clinical-stage biologic drug, immuno-oncology and autoimmune disease, recombinant human alpha-fetoprotein, (AFP, autoimmune disease indication, its targeted delivery platform, chemotherapy, cancer, healthcare practitioner, a low dose, any damage, healthy cell.
2008
( 16 years old in 2024 )
Proprietary Drugs
-
MaRS Discovery District
Suite 200 -101 College Street
Toronto, Ontario M5G 1L7
Canada
Private
developerclinical-stage biologic drugimmuno-oncology and autoimmune diseaserecombinant human alpha-fetoprotein(AFPautoimmune disease indicationits targeted delivery platformchemotherapycancerhealthcare practitionera low doseany damagehealthy cell
* We use standard office opening hours in near Alpha Cancer Technologies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Alpha Cancer Technologies is Drug Discovery business from Canada that founded in 2008 (16 years old in 2024), Alpha Cancer Technologies business is focusing on Proprietary Drugs.
Alpha Cancer Technologies headquarter office and corporate office address is located in MaRS Discovery District Suite 200 -101 College Street Toronto, Ontario M5G 1L7 Canada.
Alpha Cancer Technologies was founded in Canada.
In 2024, Alpha Cancer Technologies is currently focus on proprietary drugs sector.
Above is snippet of Google Trends for "proprietary drugs" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Alpha Cancer Technologies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
